[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516532":3},{"organization":4,"outcomesModule":7,"designInfo":75,"detailedDescription":74,"studyPopulation":74,"armGroups":81,"interventions":91,"overallOfficials":97,"centralContacts":101,"locations":106,"responsibleParty":249,"collaborators":251,"id":255,"slug":74,"hasResults":256,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":74,"eligibilityCriteria":259,"healthyVolunteers":256,"sex":260,"minAge":261,"maxAge":74,"enrollmentInfo":262,"targetDuration":74,"studyType":265,"phases":266,"briefSummary":268,"conditions":269,"keywords":272,"overallStatus":109,"whyStopped":74,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":283},{"fullName":5,"class":6},"TORL Biotherapeutics, LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":74},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Incidence and severity of adverse events and serious adverse events","Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0","up to 2 years",{"measure":14,"description":15,"timeFrame":16},"Maximum Tolerated Dose (MTD)","Highest administered dose with \\\u003C 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants","28 Days",{"measure":18,"description":19,"timeFrame":12},"Recommended Phase 2 Dose (RP2D)","Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data",[21,24,27,30,33,37,41,44,48,50,53,55,57,60,62,64,66,68,70,72],{"measure":22,"description":23,"timeFrame":12},"Objective Response Rate (ORR)","Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1",{"measure":25,"description":26,"timeFrame":12},"Duration of Response (DOR)","Time from CR or PR to objective disease progression or death to any cause",{"measure":28,"description":29,"timeFrame":12},"Progression Free Survival (PFS)","PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause",{"measure":31,"description":32,"timeFrame":12},"Time to Response (TTR)","Time from start of treatment to complete response or partial response",{"measure":34,"description":35,"timeFrame":36},"1 Year Overall Survival (1YOS)","Proportion of participants alive at 1 year from the start of treatment to death from any cause","1 year",{"measure":38,"description":39,"timeFrame":40},"2 Year Overall Survival (2YOS)","Proportion of participants alive at 2 years from the start of treatment to death from any cause","2 years",{"measure":42,"description":43,"timeFrame":12},"Number of anti-drug antibody (ADA) Positive Participants","Immunogenicity will be measured by the number of participants that are ADA positive.",{"measure":45,"description":46,"timeFrame":47},"Maximum Serum Concentration of TORL-4-500 (Cmax)","PK assessment","21 days",{"measure":49,"description":46,"timeFrame":47},"Minimum Serum Concentration of TORL-4-500 (Cmin)",{"measure":51,"description":46,"timeFrame":52},"Maximum Serum Concentration of TORL-4-500 at Steady State (Cmax,ss)","63 days",{"measure":54,"description":46,"timeFrame":52},"Minimum Serum Concentration of TORL-4-500 at Steady State (Cmin,ss)",{"measure":56,"description":46,"timeFrame":47},"Time of Maximum Serum Concentration of TORL-4-500 (Tmax)",{"measure":58,"description":59,"timeFrame":47},"Time of Minimum Serum Concentration of TORL-4-500 (Tmin)","PK Assessment",{"measure":61,"description":59,"timeFrame":52},"Time of Minimum Serum Concentration of TORL-4-500 at Steady State (Tmin,ss)",{"measure":63,"description":59,"timeFrame":52},"Terminal Half-life (t1\u002F2) of Serum TORL-4-500-ADC",{"measure":65,"description":59,"timeFrame":47},"Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-4-500",{"measure":67,"description":59,"timeFrame":52},"Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-4-500",{"measure":69,"description":59,"timeFrame":52},"Apparent volume of distribution during the terminal phase (Vz) of TORL-4-500",{"measure":71,"description":59,"timeFrame":52},"Clearance (CL) of TORL-4-500",{"measure":73,"description":59,"timeFrame":52},"Accumulation ratio (Rac) of TORL-4-500",null,{"allocation":76,"interventionModel":77,"interventionModelDescription":74,"primaryPurpose":78,"observationalModel":74,"timePerspective":74,"maskingInfo":79},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":80,"maskingDescription":74,"whoMasked":74},"NONE",[82,88],{"label":83,"type":84,"description":85,"interventionNames":86},"Monotherapy Dose Dose Finding - Part 1","EXPERIMENTAL","TORL-4-500 iv once every 3 weeks",[87],"Drug: TORL-4-500",{"label":89,"type":84,"description":85,"interventionNames":90},"Expansion as Monotherapy - Part 2",[87],[92],{"type":93,"name":94,"description":95,"armGroupLabels":96,"otherNames":74},"DRUG","TORL-4-500","antibody drug conjugate",[89,83],[98],{"name":99,"affiliation":5,"role":100},"Caroline Labib, PharmD","STUDY_CHAIR",[102],{"name":99,"role":103,"phone":104,"phoneExt":74,"email":105},"CONTACT","310-348-9636","caroline.labib@torlbio.com",[107,126,139,152,165,179,192,206,219,235],{"facility":108,"status":109,"city":110,"state":111,"zip":112,"country":113,"countryCode":114,"cosmosGeoPoint":115,"geoPoint":120,"contacts":121},"Mayo Clinic Phoenix","RECRUITING","Phoenix","Arizona","85054","United States","US",{"type":116,"coordinates":117},"Point",[118,119],-112.07404,33.44838,{"lat":119,"lon":118},[122,124],{"name":123,"role":103,"phone":74,"phoneExt":74,"email":74},"Mohamad Sonbol, MD",{"name":123,"role":125,"phone":74,"phoneExt":74,"email":74},"PRINCIPAL_INVESTIGATOR",{"facility":127,"status":109,"city":128,"state":129,"zip":130,"country":113,"countryCode":114,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Providence Medical Foundation","Fullerton","California","92835",{"type":116,"coordinates":132},[133,134],-117.92534,33.87029,{"lat":134,"lon":133},[137],{"name":138,"role":103,"phone":74,"phoneExt":74,"email":74},"Yung Lyou, MD",{"facility":140,"status":109,"city":141,"state":129,"zip":142,"country":113,"countryCode":114,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"UCLA - JCCC Clinical Research Unit","Los Angeles","90095",{"type":116,"coordinates":144},[145,146],-118.24368,34.05223,{"lat":146,"lon":145},[149],{"name":150,"role":103,"phone":151,"phoneExt":74,"email":74},"Lee Rosen, MD","310-829-5471",{"facility":153,"status":109,"city":154,"state":129,"zip":155,"country":113,"countryCode":114,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Torrance Memorial Physician Network","Torrance","90505",{"type":116,"coordinates":157},[158,159],-118.34063,33.83585,{"lat":159,"lon":158},[162,164],{"name":163,"role":103,"phone":74,"phoneExt":74,"email":74},"Justin Tiulim, MD",{"name":163,"role":125,"phone":74,"phoneExt":74,"email":74},{"facility":166,"status":109,"city":167,"state":168,"zip":169,"country":113,"countryCode":114,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Mayo Clinic Jacksonville","Jacksonville","Florida","32224",{"type":116,"coordinates":171},[172,173],-81.65565,30.33218,{"lat":173,"lon":172},[176,178],{"name":177,"role":103,"phone":74,"phoneExt":74,"email":74},"Yanyan Lou, MD",{"name":177,"role":125,"phone":74,"phoneExt":74,"email":74},{"facility":180,"status":109,"city":181,"state":168,"zip":182,"country":113,"countryCode":114,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"Florida Cancer Specialists Lake Nona Drug Development Unit","Orlando","32827",{"type":116,"coordinates":184},[185,186],-81.37924,28.53834,{"lat":186,"lon":185},[189,191],{"name":190,"role":103,"phone":74,"phoneExt":74,"email":74},"Cesar Perez, MD",{"name":190,"role":125,"phone":74,"phoneExt":74,"email":74},{"facility":193,"status":109,"city":194,"state":195,"zip":196,"country":113,"countryCode":114,"cosmosGeoPoint":197,"geoPoint":201,"contacts":202},"Mayo Clinic Rochester","Rochester","Minnesota","55905",{"type":116,"coordinates":198},[199,200],-92.4699,44.02163,{"lat":200,"lon":199},[203,205],{"name":204,"role":103,"phone":74,"phoneExt":74,"email":74},"Andrea Wahner-Hendrickson, MD",{"name":204,"role":125,"phone":74,"phoneExt":74,"email":74},{"facility":207,"status":109,"city":208,"state":209,"zip":210,"country":113,"countryCode":114,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Virginia Cancer Specialists","Lexington","Virginia","22031",{"type":116,"coordinates":212},[213,214],-79.44282,37.78402,{"lat":214,"lon":213},[217],{"name":218,"role":103,"phone":74,"phoneExt":74,"email":74},"Alexander Spira, MD",{"facility":220,"status":109,"city":221,"state":222,"zip":223,"country":224,"countryCode":225,"cosmosGeoPoint":226,"geoPoint":230,"contacts":231},"University Health Network, Princess Margaret Cancer Centre","Toronto","Ontario","M5G 2M9","Canada","CA",{"type":116,"coordinates":227},[228,229],-79.39864,43.70643,{"lat":229,"lon":228},[232,234],{"name":233,"role":103,"phone":74,"phoneExt":74,"email":74},"Erica Tsang",{"name":233,"role":125,"phone":74,"phoneExt":74,"email":74},{"facility":236,"status":109,"city":237,"state":238,"zip":239,"country":224,"countryCode":225,"cosmosGeoPoint":240,"geoPoint":244,"contacts":245},"McGill University Health Centre","Montreal","Quebec","H4A 3J1",{"type":116,"coordinates":241},[242,243],-73.58781,45.50884,{"lat":243,"lon":242},[246,248],{"name":247,"role":103,"phone":74,"phoneExt":74,"email":74},"Ramy Saleh, MD",{"name":247,"role":125,"phone":74,"phoneExt":74,"email":74},{"type":250,"investigatorFullName":74,"investigatorTitle":74,"investigatorAffiliation":74,"oldNameTitle":74,"oldOrganization":74},"SPONSOR",[252],{"name":253,"class":254},"Translational Research in Oncology","OTHER","100516532",false,"NCT06005740","A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer","Inclusion Criteria:\n\n* Advanced solid tumor\n* Measurable disease, per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Has not recovered \\[recovery is defined as NCI CTCAE, version 5.0, grade ≤1\\] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements\n* Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-4-500\n* Progressive or symptomatic brain metastases\n* Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection\n* History of significant cardiac disease\n* History of myelodysplastic syndrome (MDS) or AML\n* History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded\n* If female, is pregnant or breastfeeding","ALL","18 Years",{"count":263,"type":264},70,"ESTIMATED","INTERVENTIONAL",[267],"PHASE1","This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer.\n\nFor Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).",[270,271],"Advanced Solid Tumor","Hepatocellular Carcinoma",[273],"ADC","2025-02-27",{"date":276,"type":277},"2025-03-04","ACTUAL",{"date":279,"type":277},"2023-12-04",{"date":281,"type":264},"2026-10-31",{"name":5,"class":6},10]